biovail corp settlement delays rivals bid on generic antidepressant biovail corp reached a settlement with companies over its antidepressant drug wellbutrin xl delaying generic versions of the treatment for a few more quarters the settlement by the canadian pharmaceuticals company with anchen pharmaceuticals llp impax laboratories inc watson pharmaceuticals inc and teva pharmaceutical industries ltd followed a review by the federal trade commission that had been requested by the parties biovail had tried to block the companies from making their own versions of wellbutrin xl it said actions against impax and watson will be dismissed it said another action against abrika pharmaceuticals isnt affected in the agreement teva anchen impax and watson may not market a generic of the milligram strength wellbutrin xl until 
